A MULTICENTER OPEN-LABEL EXTENSION STUDY FOR SUBJECTS WHO PARTICIPATED IN STUDY B0151003 (ANDANTE II)

Trial Profile

A MULTICENTER OPEN-LABEL EXTENSION STUDY FOR SUBJECTS WHO PARTICIPATED IN STUDY B0151003 (ANDANTE II)

Completed
Phase of Trial: Phase II

Latest Information Update: 22 Mar 2017

At a glance

  • Drugs PF 4236921 (Primary)
  • Indications Crohn's disease
  • Focus Adverse reactions
  • Acronyms ANDANTE-II
  • Sponsors Pfizer
  • Most Recent Events

    • 26 May 2016 This trial was completed in Italy and Ireland (end date: 2016-03-01) and prematurely ended in Greece according to the European Clinical Trials Database
    • 26 Apr 2016 This trial was completed in Belgium,Austria, Sweden and Czech Republic (end date: 2016-03-01), according to the European Clinical Trials Database.
    • 25 Apr 2016 Status changed from active, no longer recruiting to completed.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top